Long-Term Safety of Fevipiprant (QAW039) in Patients with Asthma, Inadequately Controlled on Standard-of-Care Therapy: Design of The Phase III SPIRIT Trial

Autor:	S. Wang, E.M. Kerwin, M. Smolen, Barbara Knorr, M. Kato, B. Boone, J.M. Felser, J.F. Maspero
Rok vydání:	2019
Předmět:	medicine.medical_specialty Standard of care business.industry medicine Fevipiprant In patient Long term safety Intensive care medicine business medicine.disease Phase (combat) Asthma
Zdroj:	A32. ASTHMA: CLINICAL STUDIES II.
DOI:	10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1314
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::559655ddbc3614f979179bce09f681d7 https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1314 Zobrazit plný text záznamu